Jump to content

BHF-177

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Vortioxetine (talk | contribs) at 15:03, 13 December 2020 (Added SVG of structure). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

BHF-177
Identifiers
  • N-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl]-2-methyl-5-[4-(trifluoromethyl)phenyl]-4-pyrimidinamine
CAS Number
IUPHAR/BPS
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H20F3N3
Molar mass347.385 g·mol−1
3D model (JSmol)
  • C4CC2CC4CC2Nc1nc(C)ncc1-c3ccc(C(F)(F)F)cc3
  • InChI=1S/C19H20F3N3/c1-11-23-10-16(13-4-6-15(7-5-13)19(20,21)22)18(24-11)25-17-9-12-2-3-14(17)8-12/h4-7,10,12,14,17H,2-3,8-9H2,1H3,(H,23,24,25)/t12-,14+,17+/m0/s1 checkY
  • Key:ADHZHPOKTRHZGT-DXCKQFNASA-N checkY
  (verify)

BHF-177 is a compound used in scientific research which acts as a positive allosteric modulator at the GABAB receptor.[1] It was shown to reduce self-administration of nicotine in animal studies.[2]

References

  1. ^ Guery S, Floersheim P, Kaupmann K, Froestl W (November 2007). "Syntheses and optimization of new GS39783 analogues as positive allosteric modulators of GABA B receptors". Bioorganic & Medicinal Chemistry Letters. 17 (22): 6206–11. doi:10.1016/j.bmcl.2007.09.023. PMC 2278029. PMID 17884493.
  2. ^ Paterson NE, Vlachou S, Guery S, Kaupmann K, Froestl W, Markou A (July 2008). "Positive modulation of GABA(B) receptors decreased nicotine self-administration and counteracted nicotine-induced enhancement of brain reward function in rats". The Journal of Pharmacology and Experimental Therapeutics. 326 (1): 306–14. doi:10.1124/jpet.108.139204. PMC 2574924. PMID 18445779.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=BHF-177&oldid=993980583"